Numerous preparations containing eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) are commercially available. We examined changes in serum lipids/lipoproteins and the omega-3 index with various EPA/DHA formulations. Dyslipidemic subjects (N=10/arm) were randomized to daily doses of prescription fish oil (3360 mg EPA+DHA), supplemental fish oil (3340 mg EPA+DHA) or a krill oil blend (960 mg EPA+DHA); in a 6-week, open-label trial. The fish oil preparations produced significant (p<0.05) and comparable reductions in triglycerides (∼-25%); whereas the krill oil blend (KOB) resulted in a modest increase. Other lipoprotein changes were similar across treatments. The fish oil products each produced similar elevations in the omega-3 index, and more than the KOB, although all agents produced significant changes from baseline. When evaluated per gram of EPA+DHA dosed, the KOB increased the omega-3 index 2-fold more than the fish oil groups.Overall, the fish oil preparations provided comparable and favorable changes in triglycerides and the omega-3 index, which were significantly greater than those observed with the KOB.
Citation: Backes JM, Ruisinger JF, Harris KA, Gibson CA, Harris WS, et al. (2014) Evaluating the Effects of Prescription Fish Oil, Supplemental Fish Oil and a Krill Oil Blend on Serum Lipids/Lipoproteins and the Omega-3 Index: A Pilot Study. J Glycomics Lipidomics 4:121.